The Children's Cancer Fund is a nonprofit committed to supporting the fight against pediatric cancer and blood diseases by funding clinical programs, patient support services, and translational research (in partnership with Maria Fareri Children's Hospital and New York Medical College).
The Children's Cancer Fund centers its giving on pediatric cancer, blood diseases, and translational work tied to Maria Fareri Children’s Hospital and New York Medical College. A defining feature of the funder is its support for research that moves from laboratory and clinical settings toward treatment, including targeted immunotherapy, stem cell therapy, and experimental therapeutics. It also funds work on sickle cell disease and hemophilia alongside childhood cancer programs. Recent grants show a strong relationship with New York Medical College in Valhalla, NY, including a $325,125 award in 2025 and two $200,000 awards in 2024 for research assistance for childhood cancer cures and sickle cell disease. The foundation also backs a separate research project in osteosarcoma through the HOPE Super Grant, reflecting a willingness to support disease-specific work when it aligns with its broader mission. Alongside research funding, it makes direct educational support available to current or former patients and their siblings pursuing post-secondary or vocational training.
In pediatric cancer research, The Children's Cancer Fund has supported laboratory and clinical programs at Maria Fareri Children’s Hospital and New York Medical College, including clinical trials, stem cell transplant consortia, targeted immunotherapy, and developmental and experimental therapeutics. Its blood-disease work extends to sickle cell disease and hemophilia, which appear repeatedly in grant purposes and focus areas. The funder also supports cellular and gene therapy-related approaches through its active research programs, including NK cell-based immunotherapy for high-risk AML. A separate strand of giving goes to osteosarcoma research: the HOPE Super Grant supports a combinatorial immunotherapy project led by Dr. Mitchell Cairo at New York Medical College to improve survival for children and adolescents with relapsed osteosarcoma.
Typical grants cluster at the upper end of six figures, with a p25 of $125,000 and a median and p75 of $200,000. The recent record also includes a $325,125 award and a $50,000 grant, showing some spread around a core research-support pattern. The foundation appears to favor recurring support: New York Medical College received multiple awards across 2024 and 2025 for the same research assistance purpose. It is a regular funder rather than a donor-advised fund, and at least one program, the educational scholarship, accepts unsolicited applications. Several research grants are described as ongoing support rather than one-time awards.
$325K
$816K
$513K
$370K
Most grants fall between $125K and $200K, with a median of $200K.
25th Percentile
$125K
Median
$200K
75th Percentile
$200K
KAREN WOLOWNIK
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Grantmaking is regional, with 67% of grants going to recipients in New York. The strongest recipient concentration is in Valhalla, NY, through New York Medical College, and Westchester County appears repeatedly in program descriptions. Outside New York, the recent-grants list includes Monrovia, CA through St Baldricks Foundation. The recipient country distribution is entirely U.S.-based, with 4 grants, or 100%, going to U.S. recipients.
It supports pediatric cancer research, blood diseases such as sickle cell disease and hemophilia, cellular and gene therapies, immunotherapy, blood and marrow transplant, psychosocial patient and family support, and educational scholarships for survivors and siblings.
The typical grant size is $125,000 at the 25th percentile and $200,000 at both the median and 75th percentile.
Yes. New York Medical College appears in multiple recent awards across 2024 and 2025, all tied to research assistance for childhood cancer cures and sickle cell disease, indicating repeated support rather than a one-time relationship.
One active program, The Children's Cancer Fund Educational Scholarship, accepts unsolicited applications and supports current or former patients treated for childhood cancer or blood diseases, as well as their siblings, for post-secondary education or vocational training in the United States.
Most grants go to New York. The recipient distribution shows 67% of grants in the HQ state, and Valhalla, NY is the main city linked to the foundation's recent grant activity through New York Medical College.
2025
Source: IRS Form 990-PF, fiscal year 2025.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| NEW YORK MEDICAL COLLEGE | VALHALLA, NY | $325,125 | 2025 | RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE |
| NEW YORK MEDICAL COLLEGE | VALHALLA, NY | $200,000 | 2024 | RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE |
| NEW YORK MEDICAL COLLEGE | VALHALLA, NY | $200,000 | 2024 | RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE |
| ST BALDRICKS FOUNDATION | MONROVIA, CA | $50,000 | 2024 | RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE |
RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE
RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE
RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE
RESEARCH ASSISTANCE FOR CHILDHOOD CANCER CURES AND SICKLE CELL DISEASE